

1 **Sleep disorders and quality of life of women in**
2 **menopausal transition and postmenopausal**
3 **assisted in Primary Health Care: a cross-**
4 **sectional observational study protocol**

5
6
7
8
9
10

ABSTRACT

Aims: The objective of the study will be to evaluate the presence of sleep disorders, sleep quality and life of women in the menopausal transition and postmenopausal assisted in primary health care (PHC) in Divinópolis/MG.
Study design: Cross-sectional observational.
Place and Duration of Study: PHC in the municipality of Divinópolis, Minas Gerais, Brazil, between January and December 2023.
Material and methods: The present study will be carried out by professors and students of the State University of Minas Gerais (UEMG), Divinópolis Unit, with women recruited from PHC in the municipality of Divinópolis/MG, after consenting to participate in the study, by signing the Informed Consent Form (ICF). The sample will be consecutive and of convenience and then stratified according to sociodemographic variables, presence or absence of sleep disorders, sleep quality, quality of life and other variables pertinent to the study.
Discussion: Due to the lack of professional performance in primary care for sleep disorders, it is necessary to study the concomitant changes between the menopausal transition and postmenopausal processes. Given the aspects related to these disorders, there is a need for a more in-depth look at the factors that can interfere with sleep quality during this transition.
Conclusion: This study protocol aims to investigate sleep disorders and the quality of sleep and life in women during the menopausal and postmenopausal transition phases. The research seeks to identify data demonstrating the changes that occur during these phases.

11
12

Keywords: Primary Health Care; Sleep Wake Disorders; Postmenopause; Climateric.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. INTRODUCTION

According to the Brazilian Institute of Geography and Statistics, there has been a growing increase in population ageing in Brazil, especially among women, in which life expectancy has shown an average of 80.5 years [1]. Women's health undergoes specific changes with aging, especially during the menopausal transition, the period that precedes menopause and the endocrinological, biological and clinical changes of the approach to menopause begin, varying according to the age and specificity of each woman [2]. Menopause is recognized as the loss of ovarian follicular activity and non-reproductive state and is recognized after twelve consecutive months of absence from menstrual cycles, without pathological or physiological causes [3].

During the menopausal transition, the final phase of the fertile period, where irregular menstrual cycles begin until menopause, various signs and symptoms of vasomotor, psychological and cognitive origin may manifest, such as hot flashes, palpitations, mood swings, depression, irritability, anxiety, sleep disorders, memory problems, concentration, and atrophic effects, such as vaginal atrophy and bladder irritability [4].

Women in the menopausal transition and postmenopausal are more likely to experience sleep disturbances, probably due to the physiological changes of these phases [5]. The prevalence of sleep disorders varies according to the stage: from 16% to 42% in premenopausal, from 39% to 47% in perimenopausal, and from 35% to 60% in postmenopausal [6]. The factors that cause these disorders are not completely clear and vary depending on the specific symptoms. However, some contributing factors may include menopause itself, vasomotor symptoms, depression, ageing, anxiety, cardiovascular and endocrine diseases, medication use, and psychosocial factors [7,49,50,51].

Sleep is a state of minor sensorimotor activity, muscle relaxation, and a cyclical process with defined neurological and cardiorespiratory patterns. It is divided into two phases: NREM (non-rapid eye movement) sleep and REM (rapid eye movement) sleep. NREM sleep has subphases that vary according to the depth of sleep: stage 1 (falling asleep), stage 2 (light sleep), and stage 3 (deep sleep). REM sleep is the deepest phase, characterized by rapid eye movements, dreams, and information storage [8]. Good sleep quality is essential for human life, ensuring restorative, protective, immunological and energy-conserving functions. Sleep deprivation impairs mental and physical well-being by affecting functionality [9]. Sleep problems negatively impact quality of life, increasing the risk of accidents and decreasing productivity [10].

Insomnia is a sleep disorder characterized by difficulty in initiating or maintaining sleep, or in waking up earlier than desired, compromising the quality of the day. Globally, the prevalence of insomnia symptoms is approximately 30 to 35%, with an annual incidence between 7 and 15% [11,12,13]. Women are 1.41 times more likely to develop sleep disorders and 1.3 to 1.8 times more likely to have insomnia compared to men [14,15]. The incidence of insomnia increases in women in the transition from menopause to women in the reproductive phase, and worsens with age, with personal health perception being an important determinant of sleep quality [16,17].

Obstructive sleep apnea (OSA) is a common public health disorder characterized by repeated episodes of upper airway collapse during sleep [18]. According to some studies, the incidence of OSA in women increases after menopause, and it is estimated that the prevalence of this condition among women in the sixth or seventh decade of life ranges from 4% to 22%, depending on the definition used and the population examined [19,20].

Excessive daytime sleepiness (EDS) is characterized by the inability to remain awake and/or alert during the day due to poor sleep quality, medication use and comorbidities [21]. It presents itself as a common complaint in the population, which has been associated with hypertension, diabetes, allergies, depression, anxiety, and muscle contractures. In addition to these factors, others such as lifestyle habits, alcoholism,

66 sedentary lifestyle and insufficient sleep can predispose to such a framework [22,23].
67 Women tend to be more affected due to the accumulation of domestic responsibilities
68 directed at them, such as looking after the home and children [24].

69 Among the levels of health care in Brazil, Primary Health Care (PHC) refers to the
70 first level of health care, which contributes to the care of the most common needs of
71 individuals [25]. According to the Pan American Health Organization/World Health
72 Organization (PAHO/WHO), PHC is defined as the patient's first contact, and this care is
73 comprehensive and of community standard. At this level of health care, if necessary, the
74 patient's demand for other areas is screened according to their complexity. Services are
75 offered aimed at promotion, prevention, protection, diagnosis, treatment, rehabilitation, harm
76 reduction, palliative care and health surveillance [26].

77 During the phases of menopause, it is essential that women receive adequate care
78 through PHC so that their complaints are attended to with attention and care, and their
79 doubts are clarified [27]. Considering that many women report changes in sleep and quality
80 of life during the menopausal transition and postmenopausal, qualified care by health
81 professionals is essential. These professionals should guide them in an understandable,
82 objective and competent manner about the common clinical implications in this period [28].
83 PHC enables more humanized and informative care, offering comprehensive support to the
84 needs of these women.

85

86 **2. MATERIAL AND METHODS**


87

88 **2.1 Study design and ethical considerations**

89

90 The present study will be of the cross-sectional observational type, carried out by
91 professors and students at the State University of Minas Gerais (UEMG), Divinópolis Unit,
92 with women recruited from PHC in the municipality of Divinópolis/MG. The study design
93 follows the norms of the Strengthening the Reporting of Observational Studies in
94 Epidemiology (STROBE) statement [29,30] and is by the ethical standards established in the
95 Declaration of Helsinki 1961 and in the Guidelines and Regulatory Standards for research
96 involving human beings of the National Health Council of the Ministry of Health of Brazil,
97 resolutions 466/2012, 510/2016 and 580/2018 (Figure 1).

98 The present study was approved by the Human Research Ethics Committee of
99 UEMG, number 6.125.104/2023, together with the Term of Consent of the Municipal Health
100 Department of Divinópolis-MG. All patients involved will be given an Informed Consent Form
101 (ICF) and leave of absence will be allowed at any time without any charge.



102
103
104 **Figure 1.**
105 **Flow**
106 **chart**
107 **of**
108 **the**
109 **stud**
110 **y.**
111
112
113 **2.2**
114 **Sam**
115 **ple**
116 **Des**
117 **crip**
118 **tion**
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136

W

137 ly Health Strategy, in the municipality of Divinópolis/MG, Brazil, will participate in the study,
138 after consenting to participate in the study, by signing the informed consent form. The
139 sample will be consecutive and convenient and then stratified according to the variables,
140 sociodemographic, presence or absence of sleep disorders, sleep quality, quality of life and
141 other variables pertinent to the study.
142

143 **2.3 Inclusion criteria**

144
145 Women over 18 years of age in the menopausal transition or postmenopausal period
146 assisted at PHC in the city of Divinópolis/MG, agreed to participate in the study, signing the
147 informed consent form.
148

149 **2.4 Exclusion Criteria**

150
151 Women with a clinical diagnosis of cancer, using hormone replacement therapy, who
152 have undergone surgical removal of the ovaries (oophorectomy) or total hysterectomy and
153 presence of incomplete answers in the questionnaires.
154

155 **2.5 Study protocol**

156

157 **2.5.1 Clinical Evaluation Form and sociodemographic questionnaire**

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

The evaluation of the patients will be carried out at the PHC of Divinópolis-MG, where personal, clinical, and sociodemographic data will be collected, and, through self-report, if the woman is in the menopausal transition or postmenopausal, presenting symptoms from the physiological changes of these phases. Systemic blood pressure will be measured after the individual remains seated at rest for 10 minutes, using the auscultatory method. The evaluation of weight and height will be carried out using an electronic scale (model 200/5, Welmy Indústria e Comércio Ltda, São Paulo, Brazil). Body mass index (BMI) calculation will be performed using the WHO BMI Classification [31]. Neck circumference will be measured with the individual in a sitting position, at the level of the anterior border of the cricoid cartilage, both using a non-elastic tape measure with an accuracy of 1 millimeter [32]. The waist circumference will also use a non-elastic tape measure for its measurement. It will be measured at the midpoint between the lower margin of the last rib and the iliac crest, in a frontal view, on the right or left side [33].

2.5.2 Pittsburgh Sleep Quality Index (PSQI)

The PSQI was developed in 1989 and is a self-administered questionnaire that evaluates sleep quality and possible disturbances in the last month [34], validated for the Brazilian population in 2011 [35]. The questionnaire aims at the possibility of reliable and standardized measurement, leading to the differentiation of individuals with restful sleep from those with disorders that affect sleep quality [36]. This questionnaire assesses sleep quality and the presence of sleep disturbances over one month. The instrument contains nineteen self-report questions and five questions directed to the room companion. The questions are divided into seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep changes, use of sleep medications, and daytime sleep dysfunction. Adding the values of the seven components, the total score can range from 0 (zero) to 21 (twenty-one), and the higher the number, the worse the quality of sleep. A total score higher than five suggests insufficient sleep [35].

2.5.3 Insomnia Severity Index (IGI)

To measure the presence and severity of insomnia, the IGI, developed in 2001, will be used [37]. This is a brief and simple questionnaire that assesses the presence and severity of insomnia observed by the individual in the last two weeks. Validated for the Brazilian population in 2011 [38], the IGI is composed of seven items that investigate difficulty in initiating sleep, staying asleep and waking up, satisfaction with the current sleep pattern, interference with daily functioning, perception of impairment due to sleep problems, and degree of distress or worry caused by insomnia. The items are classified into five alternatives ranging from "not at all" to "very dissatisfied." The cut-off points for the classification of insomnia are: absence of significant insomnia (0 to 7), lower limit for insomnia (8 to 14), moderate clinical insomnia (15 to 21) and severe clinical insomnia (22 to 28).

2.5.4 Epworth Sleepiness Scale (ESS)

When assessing the propensity to daytime sleep, the ESS is a self-assessment instrument composed of eight items that refer to everyday situations. The responses for each item range from 0 (zero) to 3 (three), indicating the probability of falling asleep during a specific activity (0 = never, 1 = low probability, 2 = moderate probability, 3 = high probability)

208 [39]. This scale has been validated for Brazilian culture [40], where a total score equal to or
209 greater than 10 suggests the presence of EDS.

210

211 **2.5.5 Berlin Quiz**

212

213 To determine the risk for OSA, an individualized clinical questionnaire called the
214 Berlin Questionnaire will be applied [41]. This questionnaire has 10 items organized into
215 three categories as follows: apnea and snoring, daytime sleepiness systemic arterial
216 hypertension, and obesity. All positively marked responses are considered risk factors for
217 OSA. Patients will be classified as either high-risk or low-risk for OSA. A patient is
218 considered at high risk for OSA if two or more of the three categories are positive.

219

220 **2.5.6 Short Form (SF-36)**

221

222 To assess quality of life, the use of the SF-36 questionnaire is recommended. This
223 instrument, designed for clinical and research use in the United States of America, has
224 demonstrated good sensitivity in several situations, eliminating problems of overdistribution
225 in extreme scores such as "excellent" and "very poor" [42]. In 1999, the translated version of
226 the SF-36 was published and adapted to the Portuguese, adapted to the Brazilian culture.
227 This instrument, which is easy and quick to apply, is administered through interviews and
228 considers its measurement properties [43]. The SF-36 contains 36 items, of which 35 are
229 grouped into eight dimensions: functional capacity, pain, physical aspects, emotional
230 aspects, social aspects, mental health, vitality and general health status. The last item
231 evaluates the change in health over time. Each dimension has its items encoded and
232 transformed on a scale from zero (worst health status) to 100 (best health status).

233

234 **2.5.7 Menopause Rating Scale (MRS)**

235

236 Quality of life-related to climacteric symptoms will be assessed using the
237 Menopause Rating Scale (MRS). It is a scale that has been validated and translated into 8
238 languages, one of them in the Brazilian version in Portuguese [44,45,46]. It has 11 items on
239 a scale of 0 (zero) to 4 (four), indicating the absence of symptoms to severe symptoms,
240 respectively. The score is obtained through the sum of the score, the higher it is, the worse
241 the patient's symptoms and quality of life. It can be divided into MRS domains: score of 0-4
242 points, indicating absent symptoms, 5-8 points mild symptoms, 9-15 points for moderate
243 symptoms, greater than or equal to 16 points for severe symptoms [46]. The time to answer
244 the questionnaires and the evaluation form will be approximately 15 minutes.

245

246 **2.6 Quality Control**

247

248 The researchers responsible for data acquisition in this study will receive specific
249 training to ensure data quality. Periodic external monitoring will be carried out to verify the
250 correct application of the methodology for the acquisition of information and the performance
251 of the different tests.

252

253 **2.7 Statistical analysis**

254

255 First, a pilot study will be carried out to determine the sample size calculation. The
256 Kolmogorov-Smirnov normality test will be implemented to determine the presence or
257 absence of normality in the data. Numerical data will be presented as mean and standard
258 deviation for variables with normal distribution, and median and interquartile range for those
259 with asymmetric distribution. Categorical data will be described as a percentage of the total
260 and as an absolute number. In the stratification of the sample, the student's t-test will be

261 performed when it is necessary to compare paired samples. For comparisons between
262 quantitative variables, the student's t-test or the non-parametric Mann-Whitney test will be
263 used. When the variables were qualitative, the Chi-square test or Fisher's exact test will be
264 used. Correlations between continuous variables will be performed with Pearson's
265 correlation test or Spearman's correlation test. For the statistical treatment, the statistical
266 software (Statistical Package for Social Sciences SPSS 13.0® (Chicago, IL, USA) will be
267 used. The level of statistical significance will be set at 5% for all tests ($p < 0.05$), for a 95%
268 confidence interval.

269
270
271

3. RESULTS

272
273
274
275
276
277
278
279

It is expected to find changes in sleep quality and the presence of sleep disorders in both menopausal and postmenopausal women assisted in PHC, which may influence their quality of life. It is pertinent to quantify and analyze the difference between these changes in both groups. This issue is decisive in the inclusion of intervention and treatment programs for sleep disorders. In addition, basal nocturnal polysomnography, the gold standard test to assess sleep, is expensive and difficult to access for patients assisted in PHC, justifying the use of subjective tools such as questionnaires to assess sleep in this population.

280
281

4. DISCUSSION

282
283
284
285
286
287
288
289
290
291
292

Due to the increase in life expectancy in the world population, and especially the greater predominance of females, it is necessary to understand the phases that these women experience in different periods of their lives. Menopause is a complex period of major changes in a woman's body and understanding its relationship with sleep quality is important to contribute to improving the quality of life for this specific population. And although few studies compare sleep disorders and the quality of life of women in the menopausal transition and postmenopausal, it is an important topic, considering the prevalence of these disorders, which are now considered a public health problem [47,48]. In addition, complete nocturnal polysomnography and actigraphy have a higher cost. Therefore, the use of subjective tools such as questionnaires to assess sleep in this population is justified.

293
294

5. CONCLUSION

295
296
297
298
299
300
301

This study protocol aims to describe the investigation of sleep disorders, as well as the quality of sleep and life in women in the menopausal and postmenopausal transition phases. The research aims to identify data that demonstrate the concomitant changes present in these phases. These findings will contribute to the development of public health policies aimed at improving sleep and, consequently, the quality of life of these women, based on a comprehensive approach to women's health.

302
303
304

ACKNOWLEDGEMENTS

305
306
307
308
309
310

To the Institutional Research Support Program of the State University of Minas Gerais (PAPq/UEMG) who invested with LVSR and MCS scientific initiation scholarships and NSFJ advisor professor scholarships.

311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361

AUTHORS' CONTRIBUTIONS

All authors contributed to the conception and design of the study. LVSR, NSFJ, LTP, MCS, and ASF contributed significantly to the writing of this article. NSFJ and LTP were involved in the critical review of the manuscript. This protocol paper was written by LVSR, NSFJ, and LTP with assistance from all co-authors. All authors read and approved the final manuscript.

ETHICAL APPROVAL AND CONSENT

The present study was approved by the Human Research Ethics Committee of UEMG, under opinion number 6.125.104/2023, together with the Term of Consent of the Municipal Health Department of Divinópolis-MG. All patients involved will be written consent and leave will be allowed at any time at no cost.

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include list the name, version, model, and source of the generative AI technology and as well as the all input prompts provided to a generative AI technology

Details of the AI usage are given below:

- 1.
- 2.
- 3.

6. REFERENCES

1. Instituto Brasileiro de Geografia e Estatística. Estatísticas Sociais, 26 de novembro de 2020. Disponível em: <https://agenciadenoticias.ibge.gov.br/agencia-sala-de-imprensa/2013-agencia-de-noticias/releases/29502-em-2019-expectativa-de-vida-era-de-76-6-anos>. Acesso em 19 de julho de 2022.
2. Warren MP. Missed symptoms of menopause. *Int J Clin Pract*. 2007;61(12):12.
3. Mustafa MM, Souza EPP, Sena AB. Menopausa precoce no Brasil: umarevisãobibliográficaintegrativa. *Res Soc Dev*. 2021;10(14):1-8.
4. Stojanovska L, Apostolopoulos V, Polman R, Borkoles E. To exercise, or, not to exercise, during menopause and beyond. *Maturitas*. 2014;77(4):318-23.

- 362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
5. Kravitz HM, Ganz PA, Bromberger J. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. *Menopause*. 2003;10(1):19-28.
 6. Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. *ObstetGynecol Clin North Am*. 2011;38(3):567-86.
 7. Lee J, Han Y, Cho HH, Kim MR. Sleep Disorders and Menopause. *J Menopausal Med*. 2019;25(2):83-7.
 8. Dement WC. A personal history of sleep disorders medicine. *J Neurophysiol Clin*. 1990;7(1):17-48.
 9. Neves GSML, Macedo P, Gomes MMG. Transtornos do sono: atualização (1/2). *Rev Bras Neurol*. 2017;53(3):19-30.
 10. Buckworth J, Dishman RK. *Exercise psychology*. 2nd ed. Champaign: Human Kinetics; 2002. p. 1-528.
 11. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epidemiology of insomnia: a longitudinal study in a UK population. *Sleep*. 2007;30(3):274-80.
 12. Ohayon MM, Reynolds CF. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). *Sleep Med*. 2009;10(9):952-60.
 13. Leblanc M, Mérette C, Savard J, Ivers H, Baillargeon L, Morin CM. Incidence, and risk factors of insomnia in a population-based sample. *Sleep*. 2009;32(8):1027-37.
 14. Krystal AD, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. *Sleep*. 2003;26(7):793-9.
 15. Zhang B, Wing YK. Sex Differences in Insomnia: A Meta-Analysis. *Sleep*. 2006;29(1):85-93.
 16. Ballot O, Ivers H, Morin JCM. Sleep Disturbances During the Menopausal Transition: The Role of Sleep Reactivity and Arousal Predisposition. *Behav Sleep Med*. 2021;20(4):500-12.
 17. Souza CL, Aldrighi JM, Filho GL. Qualidade do sono em mulheres paulistanas no climatério. *Rev Assoc Med Bras*. 2005;51(3):3.
 18. Sánchez-de-la-Torre M, Campos-Rodríguez F, Barbé F. Obstructive sleep apnea and cardiovascular disease. *Lancet Respir Med*. 2013;1(1):61-72.
 19. Peppard TE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol*. 2013;177(9):1006-14.
 20. Koo SK, et al. Obstructive sleep apnea in postmenopausal women: a comparative study using drug induced sleep endoscopy. *Braz J Otorhinolaryngol*. 2017;83(3):285-91.

- 415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
21. Silva K, Cattani AN, Hirt MC, Peserico A, Silva RM, Beck CLC. Somnolenciadiurnaexcesiva y losefectos del trabajoen la salud de trabajadores de enfermería. *Enferm Glob*. 2020;58(58):276-88.
 22. Gooneratne NS, et al. Functional outcomes of excessive daytime sleepiness in older adults. *J Am Geriatr Soc*. 2003;51(5):642-9.
 23. Guimarães CLH, Carvalho LB, Yanaguibashi G, Prado GF. Physically active elderly women sleep more and better than sedentary women. *Sleep Med*. 2008;9(5):94-488.
 24. Spindola T, Santos RS. Mujer y trabajo—La historia de vida de madrestrabajadorasen enfermería. *Rev Lat Am Enfermagem*. 2003;11(5):593-600.
 25. Portela GZ. AtençãoPrimária à Saúde: um ensaiosobreconceitosaplicadosaos estudosnacionais. *Physis*. 2017;27(2):255-76.
 26. Brasil. Portaria nº 2.436, de 21 de setembro de 2017. Consolidação das normassobre as políticasnacionais de saúde do Sistema Único de Saúde. Política Nacional de AtençãoBásica (PNAB). *DiárioOficial da República Federativa do Brasil*. Brasília DF, art. 2., 21 de setembro de 2017.
 27. Vieira TMM, et al. Vivenciando o climatério: percepções e vivências de mulheresatendidasnaatenção básica. *Enferm Foco*. 2018;9(2):40-5.
 28. Pimenta FAP, et al. Avaliação da qualidade de vida de aposentados com a utilização do questionário SF-36. *Rev Assoc Med Bras*. 2008;54(1):55-60.
 29. Von EE, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ*. 2007;335(4):806-8.
 30. Malta M, Cardoso LO, Bastos FI, Magnanini MMF, Silva CMF. STROBE initiative: guidelines on reporting observational studies. *Rev Saude Publica*. 2010;44(3):559-65.
 31. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. *WHO Tech Rep Ser*. 2000;894(1):1-253.
 32. Zen V, Fuchs FD, Wainstein MV. Neck circumference and central obesity are independent predictors of coronary artery disease in patients undergoing coronary angiography. *Am J Cardiovasc Dis*. 2012;2(4):323-30.
 33. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. *WHO Tech Rep Ser*. 2000;894(1):1-253.
 34. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*. 1989;28(2):193-213.

- 466 35. Bertolazi NA, Fagondes SC, Hoff LS, Dartora EG, Miozzo IC, Barba ME. Validation
467 of the Brazilian Portuguese version of the Pittsburgh Sleep Quality Index. *Sleep*
468 *Med.* 2011;5(1):12-70.
469
- 470 36. Ribeiro HL, et al. Perfil clínico-epidemiológico da sonolência diurna excessiva quanto a
471 sua avaliação por intermédio da aplicação de escalas subjetivas do sono: Escala de
472 Sonolência de Epworth e Índice de Qualidade do Sono de Pittsburgh. *Rev Uningá.*
473 2020;57(1):39-50.
474
- 475 37. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an
476 outcome measure for insomnia research. *Sleep Med.* 2001;2(4):297-307.
477
- 478 38. Castro LS. Adaptação e validação do Índice de Gravidade de Insônia (IGI):
479 caracterização populacional, valores normativos e aspectos associados. [dissertation].
480 São Paulo; 2011. p. 1-104.
481
- 482 39. Johns MW. A new method for measuring daytime sleepiness: the Epworth
483 sleepiness scale. *Sleep.* 1991;14(6):540-5.
484
- 485 40. Bertolazi AN, Fagondes SC, Hoff LS, Pedro D, Barreto SSM, Johns MW.
486 Portuguese-language version of the Epworth sleepiness scale: validation for
487 use in Brazil. *J Bras Pneumol.* 2009;35(1):877-83.
488
- 489 41. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin
490 Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Intern*
491 *Med.* 1999;131(7):485-91.
492
- 493 42. Ware JJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
494 Conceptual framework and item selection. *Med Care.* 1992;30(6):83-473.
495
- 496 43. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para a
497 língua portuguesa e validação do questionário genérico de avaliação de qualidade de
498 vida SF-36 (Brasil SF-36). *Rev Bras Reumatol.* 1999;39(3):143-50.
499
- 500 44. Potthoff P, Heinemann LAJ, Schneider HPG, Rosemeier HP, Hauser GA.
501 Menopause-Rating Skala (MRS): Methodische Standardisierung in der
502 deutschen Bevölkerung. *Zentralbl Gynakol.* 2000;122(5):280-6.
503
- 504 45. Heinemann K, Assmann A, Möhner S, Schneider HPG, Heinemann LAJ. Reliabilität
505 der Menopause-Rating-Skala (MRS). Untersuchung für die Deutsche Bevölkerung.
506 *Zentralbl Gynakol.* 2002;124(3):161-3.
507
- 508 46. Heinemann LA, Potthoff P, Schneider HPG. International versions of the Menopause
509 Rating Scale (MRS). *Health Qual Life Outcomes.* 2003;30(1):28.
510
- 511 47. Brown L, Hunter MS, Chen R, Crandall CJ, Gordon JL, Mishra GD, Rother V,
512 Joffe H, Hickey M. Promoting good mental health over the menopause
513 transition. *The Lancet.* 2024 Mar 9;403(10430):969-83.
514
- 515 48. Terzic S, Bapayeva G, Kadroldinova N, Sarria-Santamera A, Gusmanov A,
516 Semenova Y, Aimagambetova G, Laganà AS, Chiantera V, Ukybassova T, Kongrtay
K. Menopausal Status Impact on the Quality of Life in Kazakhstani Healthcare

- 517 Workers: A Cross-sectional Study. *Journal of General Internal Medicine*. 2024 Feb
518 5:1-9.
- 519 49. Jayadharani, C., Devi, R. G. and Priya, A. J. (2020) "Effect of Peppermint Oil among
520 Sleep Apnea Individuals", *Journal of Pharmaceutical Research International*, 32(26),
521 pp. 98–101. doi: 10.9734/jpri/2020/v32i2630843.
- 522 50. Thorpy MJ. Classification of sleep disorders. *Neurotherapeutics*. 2012 Oct
523 1;9(4):687-701
- 524 51. Ophoff D, Slaats MA, Boudewyns A, Glazemakers I, Van Hoorenbeeck K,
525 Verhulst SL. Sleep disorders during childhood: a practical review. *European*
526 *journal of pediatrics*. 2018 May;177:641-8.
- 527

528

529